Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Wajeeh Khan

Tango Therapeutics (TNGX) Stock Soars on Pancreatic Cancer Trial Results

Boston-headquartered Tango Therapeutics (TNGX) stock surged on Monday, driven by encouraging results from a pancreatic cancer trial.

TNGX is a clinical-stage biotech firm focused on discovering and delivering next-gen precision cancer medicines, and the pancreatic cancer trial appears to have validated its therapeutic approach in a particularly difficult-to-treat cancer type.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.